UIC
CLBT icon

Uniplan Investment Counsel’s Cellebrite CLBT Stock Holding History

Uniplan Investment Counsel’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-752
Closed -$14.6K – 181
2025
Q1 		$14.6K Buy
+752
New +$15.8K ﹤0.01% 143

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
AE
Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Uniplan Investment Counsel's CLBT Position: Q2 2025 in Review

Uniplan Investment Counsel sold out of Cellebrite (CLBT) in Q2 2025, closing a stake of 752 shares — an estimated $14.6K sold.

Uniplan Investment Counsel first reported a position in CLBT in Q1 2025 and held it in 1 quarter. The position peaked at $14.6K in Q1 2025. 209 funds tracked by Wall St. Rank hold CLBT as of Q2 2025.

  • Uniplan Investment Counsel reported no remaining Cellebrite position as of Q2 2025 after selling out during the quarter.
  • Uniplan Investment Counsel sold 752 Cellebrite shares in Q2 2025, an estimated $14.6K.
  • Uniplan Investment Counsel first reported a position in Cellebrite in Q1 2025 and held it in 1 quarter.
  • Uniplan Investment Counsel's Cellebrite position peaked at $14.6K in Q1 2025.
  • 209 funds tracked by Wall St. Rank held Cellebrite as of Q2 2025.

Based on Uniplan Investment Counsel's 13F filing for Q2 2025, filed 14 Aug 2025.